Insulet Misses Where it Counts
Insulet (NAS: PODD) reported earnings on Aug. 8. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), Insulet met expectations on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue increased significantly and GAAP loss per share dropped.
Gross margins dropped, operating margins improved, net margins increased.
Insulet notched revenue of $51.0 million. The 15 analysts polled by S&P Capital IQ expected a top line of $51.8 million on the same basis. GAAP reported sales were 58% higher than the prior-year quarter's $32.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.30. The 15 earnings estimates compiled by S&P Capital IQ predicted -$0.25 per share. GAAP EPS were -$0.30 for Q2 versus -$0.42 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 43.8%, 130 basis points worse than the prior-year quarter. Operating margin was -20.6%, 1,580 basis points better than the prior-year quarter. Net margin was -28.4%, 3,190 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $55.8 million. On the bottom line, the average EPS estimate is -$0.21.
Next year's average estimate for revenue is $215.9 million. The average EPS estimate is -$0.91.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 69 members out of 114 rating the stock outperform, and 45 members rating it underperform. Among 39 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 25 give Insulet a green thumbs-up, and 14 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Insulet is outperform, with an average price target of $23.04.
- Add Insulet to My Watchlist.
The article Insulet Misses Where it Counts originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.